uniQure

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

~ Data from largest gene therapy study in hemophilia B showed sustained therapeutic effect at 18-months and statistical superiority in reducing annualized bleeding rate compared to baseline FIX prophylactic therapy; Submissions of marketing applications on track for the first half of 2022 ~

uniQure Announces 2021 Financial Results and Highlights Recent Company Progress

LEXINGTON, Mass. and AMSTERDAM, Feb. 07, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the dosing of the first two patients in its European open-label Phase Ib/II clinical trial of AMT-130, a potential one-time gene-therapy approach for the treatment of Huntington's disease. The clinical trial is taking place at several sites in Poland, the United Kingdom and Germany.

uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington's Disease

Coca-Cola

Cia de Saneamento Basico do Estado de Sao Paulo

Investors may want to consider the following non-cyclical stocks, as their earnings yields (as calculated via Joel Greenblatt (Trades, Portfolio)'s method) are outperforming the 20-year high-quality market corporate bond spot rate of 3.07% as of the writing of this article.

3 High Return Non-Cyclical Stocks

QURE's share price took a 30% dip following the release of its Phase-1/2 clinical trial data on its Pipeline Therapy AMT-131 for the treatment of Huntington's Disease. Despite robust Phase-3 clinical data for its main therapy AMT-061 for the treatment of Hemophilia-B, QURE is still trading close to its 52-week low.

uniQure: Betting On Hemophilia-B Cure

The heavy selling pressure might have exhausted for uniQure (QURE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging 33.5% in 4 Weeks, Here's Why the Trend Might Reverse for uniQure (QURE)

uniQure (QURE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

uniQure (QURE) Upgraded to Buy: Here's Why

uniQure (QURE) reports initial data on the first four patients enrolled in the lower-dose cohort of its ongoing phase I/II clinical trial of AMT-130 for treating Huntington's disease.

uniQure (QURE) Falls on Data From Huntington's Disease Study

The stock price of Uniqure NV (NASDAQ: QURE) fell by over 29% today. This is why it happened.

Uniqure Stock (QURE): Why The Price Substantially Fell Today

UniQure NV (NASDAQ: QURE) announced initial observations on the first four patients enrolled in the lower-dose cohort of Phase 1/2 trial of AMT-130 for Huntington's disease.  AMT-130 was generally well tolerated at the lower dose of 6x1012 vector genomes (vg).

UniQure Shares Fall After Clinical Update From Huntington's Disease Gene Therapy Trial

~ Treatment was well tolerated with no significant safety issues

uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's Disease

CSL Behring and uniQure N.V.'s (NASDAQ: QURE) etranacogene dezaparvovec, a hemophilia B gene therapy, achieved the pre-specified primary endpoint of non-inferiority in annualized bleeding rate (ABR) compared to baseline Factor IX (FIX) prophylactic treatment.

CSL Behring, UniQure's Hemophilia B Gene Therapy Hits Primary Endpoint

~ Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annualized bleeding rate after stable Factor IX (FIX) expression, assessed at 18 months following a single dose of etranacogene dezaparvovec ~

uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B

QURE is a leader in gene therapy, and has the first commercially licensed gene therapy manufacturing facility. Utilizing their industry leading technology, they are developing treatments and cures for genetic diseases (e.g., Huntington's and hemophilia B).

UniQure: Leading Gene Therapy Company

The recent rise can be attributed to its Q3 loss of $0.79 per share, which was better than the consensus estimate of $1.05 loss per share.

What's Next For UniQure Stock After A 10% Rise In A Month?

~ No Significant Safety Concerns Observed in First Four Patients Enrolled in Higher-dose Cohort ~

uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's Disease

LEXINGTON, Mass. and AMSTERDAM, Nov. 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences:

uniQure to Participate in Upcoming Industry Conferences in November

~ Completed 78-week follow-up for hemophilia B pivotal study, with top-line data expected by year-end 2021 ~

uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

Biotech Executive Brings Extensive Experience Developing Advanced Therapies and Regenerative Medicines Biotech Executive Brings Extensive Experience Developing Advanced Therapies and Regenerative Medicines

uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors

UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will uniQure (QURE) Report Negative Q3 Earnings? What You Should Know

Oral Presentation to Highlight AMT-191 for Fabry Disease Oral Presentation to Highlight AMT-191 for Fabry Disease

uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)

LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences:

uniQure to Participate in Multiple Upcoming Industry Conferences in October

Robert Gut, Director at Uniqure (NASDAQ:QURE), made a large insider sell on September 21, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Gut sold 4,500 shares of Uniqure at a price of $36.61.

Director Of Uniqure Sold $164.75 Thousand In Stock

MeiraGTx Holdings plc

Solid Biosciences

Sarepta Therapeutics

Voyager Therapeutics

The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others

5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal

Match Group

Tandem Diabetes Care

This Simple Thing Sent These 3 Nasdaq Stocks Soaring Tuesday

LEXINGTON, Mass. and AMSTERDAM, Sept. 07, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences:

News for uniQure Stock (QURE)